Cytocom, Inc. (CBLI) Comparison with companies in other sectors?

Cytocom, Inc. has a share price of 71.42M. You can analyze Cytocom, Inc. (CBLI) competitors across different market sectors through stock heatmaps.

What are CBLI's NET and operating margins?

Cytocom, Inc. (CBLI) operating margin is around -9.84, and net profit margin is approximately -9.12 as of the latest reports.

In what way does CBLI's earnings per share (EPS) trend reflect its financial momentum?

Cytocom, Inc. (CBLI) EPS is N/A (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Cytocom, Inc. is N/A, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Cytocom, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Cytocom, Inc. like P/E which is -16.38, P/B which is 19.52, and PEG which is -0.16. Compare them with sector averages to evaluate if the stock is priced fairly.

Cytocom, Inc.

CBLI•NASDAQ

Healthcare

Biotechnology

$3.17

$-0.25(-7.31%)

Cytocom, Inc. (CBLI) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

P/E Ratio

ROE

-1.60%

Net Margin

-9.12%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$226.39M

Shares OutstandingTotal number of shares issued

$71.42M

Book Value/ShareNet worth per share

$0.16

Revenue/ShareAnnual revenue per share

$0.02

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

Net MarginNet income as percentage of revenue

-912.16%

Operating MarginOperating income as percentage of revenue

-983.70%

ROEReturn on shareholders' equity

-160.02%

ROAReturn on total assets

-103.47%

ROCEReturn on capital employed

-128.47%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.19

Cash/ShareCash and equivalents per share

$0.18

FCF YieldFree cash flow as percentage of market cap

-1.05%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for CBLIFinancial Ratios Analysis details for CBLI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for CBLISector Benchmarking details for CBLI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Cytocom, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Cytocom, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Cytocom, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Cytocom, Inc.

For Cytocom, Inc., essential financial indicators include EPS -, PE -, and ROE -1.60. These key ratios reveal insights into Cytocom, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Cytocom, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Cytocom, Inc.

Metrics like Net Margin -912.16% and ROA -103.47% shed light on how well Cytocom, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Cytocom, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Cytocom, Inc.

Using ratios such as P/B Ratio 19.52 and PEG Ratio -0.16, investors can assess whether Cytocom, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Cytocom, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Cytocom, Inc.

Financial health indicators, such as Debt/Equity Ratio - and Cash Flow $-0.19, provide a snapshot of Cytocom, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Cytocom, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Cytocom, Inc.

Investing in Cytocom, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Cytocom, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;